AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15146228 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (TT and quiet time)
Number of subjects: 18
Study 11730179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 110, 220, 330, and 440 microg, twice daily
Number of subjects: 153
Study 11730179 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 500 and 1,000 microg, twice daily
Number of subjects: 153
Study 11730179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 11730179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone 7.5 mg daily
Number of subjects: 153
Study 9155405 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana flakes
Number of subjects: 31
Study 9155405 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment for diarrhea
Number of subjects: 31
Study 7962423 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) imaging in PCOS patients
Number of subjects: 32
Study 7962423 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients with ovarian thickened tunica
Number of subjects: 32
Study 7962423 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients
Number of subjects: 32
Study 7962423 — intervention group
Group type: EXPERIMENTAL
Intervention: TVS imaging
Number of subjects: 32
Study 29775698 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 100
Study 29775698 — intervention group
Group type: COMPARATOR
Intervention: Control (nonplacement of TachoSil)
Number of subjects: 100
Study 26797318 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) + Parent Training (PT)
Number of subjects: 128
Study 26797318 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 128
Study 26797318 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study experience
Number of subjects: 128
Study 25003980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy
Number of subjects: 105
Study 25003980 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask
Number of subjects: 105
Study 22613099 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus Bethanacol (OB)
Number of subjects: 22
Study 22613099 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Placebo (PP)
Number of subjects: 22
Study 22613099 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole/Placebo (OP)
Number of subjects: 22
Study 22613099 — intervention group
Group type: COMPARATOR
Intervention: Bethanacol/Placebo (BP)
Number of subjects: 22
Study 20436439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 45
Study 20436439 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 45
Study 18954540 — intervention group
Group type: EXPERIMENTAL
Intervention: roller bar mouse
Number of subjects: 15
Study 18954540 — intervention group
Group type: COMPARATOR
Intervention: conventional mouse
Number of subjects: 15
Study 16171291 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 0
Study 16171291 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 0
Study 16171291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12787319 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotrophins
Number of subjects: 0
Study 12787319 — intervention group
Group type: EXPERIMENTAL
Intervention: Small molecule mimetics
Number of subjects: 0
Study 10918646 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretic therapy
Number of subjects: 0
Study 10918646 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravenous beta blockade
Number of subjects: 0
Study 10918646 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 10918646 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers or magnesium
Number of subjects: 0
Study 8872727 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 18
Study 8872727 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 18
Study 1640282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib polysaccharide conjugated to outer membrane protein complex of Neisseria meningitidis (PRP‐OMP)
Number of subjects: 458
Study 1640282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib polysaccharide‐tetanus toxoid conjugate (PRP‐T)
Number of subjects: 458
Study 1640282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib oligomers conjugated to the mutant diphtheria toxin CRM197 (HbOC)
Number of subjects: 458
Study 1640282 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconjugated PRP
Number of subjects: 458
Study 1640282 — intervention group
Group type: COMPARATOR
Intervention: All three vaccines (PRP‐OMP, PRP‐T, HbOC)
Number of subjects: 458
Study 6725168 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management program ($10.00 for opiate-free urine specimens)
Number of subjects: 20
Study 6725168 — intervention group
Group type: COMPARATOR
Intervention: Control group ($5.00 for providing a specimen twice weekly)
Number of subjects: 20
Study 6725168 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management program
Number of subjects: 20
Study 6725168 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 31479116 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized prehospital management (OPM) based on the Los Angeles Motor Scale (LAMS) with a cut point ≥4
Number of subjects: 116
Study 31479116 — intervention group
Group type: COMPARATOR
Intervention: Management in a Mobile Stroke Unit (MSU)
Number of subjects: 116
Study 31479116 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMS at a cut point of 4 or higher
Number of subjects: 116
Study 29798149 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized target delineation in IMRT (experimental group)
Number of subjects: 50
Study 29798149 — intervention group
Group type: COMPARATOR
Intervention: Routine delineation of target areas (control group)
Number of subjects: 50
Study 29798149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 26880141 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 1116
Study 26880141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticker reminders
Number of subjects: 1116
Study 26880141 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine reminder)
Number of subjects: 1116
Study 24582119 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine (8 mg)
Number of subjects: 0
Study 24582119 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine extended‐release (4 mg)
Number of subjects: 0
Study 24582119 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 22086749 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 48
Study 22086749 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 48
Study 22086749 — intervention group
Group type: COMPARATOR
Intervention: First Generation Antipsychotics (FGAs) - Haloperidol or Trifluoperazine
Number of subjects: 48
Study 19464313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical processing of T-junctions
Number of subjects: 0
Study 19464313 — intervention group
Group type: COMPARATOR
Intervention: Retinal processing of T-junctions
Number of subjects: 0
Study 17412741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 18325
Study 17412741 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 18325
Study 16334880 — intervention group
Group type: EXPERIMENTAL
Intervention: Videophone assistance (telemedicine group)
Number of subjects: 32
Study 16334880 — intervention group
Group type: COMPARATOR
Intervention: Standard home hospitalization care (control group)
Number of subjects: 32
Study 12190675 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloanal J pouch anastomosis
Number of subjects: 64
Study 12190675 — intervention group
Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 64
Study 9689828 — intervention group
Group type: COMPARATOR
Intervention: GH deficiency (GHD)
Number of subjects: 575
Study 9689828 — intervention group
Group type: COMPARATOR
Intervention: Obesity (OB)
Number of subjects: 575
Study 8092094 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately protein‐restricted diet (0.8 g.kg body wt‐1.d‐1)
Number of subjects: 22
Study 8092094 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted protein diet (> 1.6 g.kg body wt‐1.d‐1)
Number of subjects: 22
Study 2679238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 7.5 mg/kg (group 1)
Number of subjects: 60
Study 2679238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 1.5 mg/kg (group 2)
Number of subjects: 60
Study 2679238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 2.0 mg/kg (group 3)
Number of subjects: 60
Study 2679238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 60
Study 1189983 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg vitamin K1 (Konakion) administered intravenously
Number of subjects: 0
Study 1189983 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (Marevan)
Number of subjects: 0
Study 1189983 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg vitamin K1 (Konakion)
Number of subjects: 0
Study 28414496 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 16
Study 28414496 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 16
Study 28414496 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 16
Study 28414496 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit Symbol Substitution Test (DSST)
Number of subjects: 16
Study 28414496 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail-Making Test
Number of subjects: 16
Study 25675062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections of local anesthetic (lidocaine 0.5%) 6 mL
Number of subjects: 120
Study 25675062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections with local anesthetic (lidocaine 0.5%) 5 mL mixed with 1 mL of steroids and 6 mg of betamethasone
Number of subjects: 120
Study 25675062 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful group of lumbar interlaminar epidural injections of local anesthetic (lidocaine 0.5%) 6 mL
Number of subjects: 120
Study 25675062 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful group of lumbar interlaminar epidural injections with local anesthetic (lidocaine 0.5%) 5 mL mixed with 1 mL of steroids and 6 mg of betamethasone
Number of subjects: 120
Study 24056293 — intervention group
Group type: EXPERIMENTAL
Intervention: AT substitution in children with AT activity below 0.55 kIU/l (n = 36)
Number of subjects: 85
Study 24056293 — intervention group
Group type: COMPARATOR
Intervention: No AT substitution (n = 39)
Number of subjects: 85
Study 24056293 — intervention group
Group type: COMPARATOR
Intervention: Historical control without AT substitution (n = 10)
Number of subjects: 85
Study 24056293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged continuous ASP treatment
Number of subjects: 85
Study 21412424 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d for 18 months
Number of subjects: 89
Study 21412424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 19110158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer depth greater than 3 mm
Number of subjects: 54
Study 19110158 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein greater than 3.2 mg/dL
Number of subjects: 54
Study 19110158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ulcer depth and C-reactive protein
Number of subjects: 54
Study 19110158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer depth greater than 3 mm or C-reactive protein greater than 3.2 mg/dL
Number of subjects: 54
Study 19110158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer depth greater than 3 mm or erythrocyte sedimentation rate greater than 60 mm/h
Number of subjects: 54
Study 17227995 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-DI (intensified treatment with six 2-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 mg/m2/day by 4-hour infusion for 3 days])
Number of subjects: 497
Study 17227995 — intervention group
Group type: COMPARATOR
Intervention: Regimen-C (conventional treatment with six 3-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 mg/m2/day by 4-hour infusion for 3 days])
Number of subjects: 497
Study 17227995 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-DI
Number of subjects: 497
Study 15172271 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (EVH)
Number of subjects: 108
Study 15172271 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvest (OVH)
Number of subjects: 108
Study 11829390 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss (BO) with Bio‐Gide (BG)
Number of subjects: 21
Study 11829390 — intervention group
Group type: COMPARATOR
Intervention: Open‐flap debridement (OFD)
Number of subjects: 21
Study 9736420 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) (enoxaparin, 1.5 mg/kg/day) subcutaneously (sc) once daily for 72 hours
Number of subjects: 18
Study 9736420 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) (initial infusion rate 450 IU/kg/day) continuous intravenous (iv) for 72 hours
Number of subjects: 18
Study 7914888 — intervention group
Group type: EXPERIMENTAL
Intervention: +2 Gz
Number of subjects: 9
Study 7914888 — intervention group
Group type: EXPERIMENTAL
Intervention: +3 Gz
Number of subjects: 9
Study 7914888 — intervention group
Group type: EXPERIMENTAL
Intervention: +4 Gz
Number of subjects: 9
Study 7914888 — intervention group
Group type: EXPERIMENTAL
Intervention: +5 Gz
Number of subjects: 9
Study 2690927 — intervention group
Group type: EXPERIMENTAL
Intervention: isovolaemic haemodilution
Number of subjects: 25
Study 2690927 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 25
Study 779390 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg body weight given intramuscularly 1 hour before anaesthesia
Number of subjects: 68
Study 779390 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg body weight given intravenously 5 minutes prior to induction
Number of subjects: 68
Study 779390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intramuscular and intravenous atropine in the above-mentioned doses
Number of subjects: 68
Study 779390 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.015 mg/kg body weight intravenously 5 minutes prior to induction
Number of subjects: 68
Study 779390 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of atropine
Number of subjects: 68
Study 779390 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of atropine
Number of subjects: 68
Study 31981777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ginger extract
Number of subjects: 360
Study 31981777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ginger extract (T3)
Number of subjects: 360
Study 31981777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% ginger extract (T4)
Number of subjects: 360
Study 31981777 — intervention group
Group type: COMPARATOR
Intervention: 0% ginger extract (Control)
Number of subjects: 360
Study 30407077 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led Healthy Lifestyle Program (HEBAT module)
Number of subjects: 2635
Study 30407077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2635
Study 26293616 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 1616
Study 25039929 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse simulator riding
Number of subjects: 47
Study 22462516 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment, multifactorial interventions, and nurse-led care coordination
Number of subjects: 1281
Study 22462516 — intervention group
Group type: COMPARATOR
Intervention: Care as usual by the general practitioner (GP)
Number of subjects: 1281
Study 21374929 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 microg ethinylestradiol (EE) with 2.0 mg cyproterone acetate/day
Number of subjects: 90
Study 21374929 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol (EE) with 2.0 mg dienogest/day
Number of subjects: 90
Study 21374929 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol (EE) with 3.0 mg drospirenone/day
Number of subjects: 90
Study 21374929 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 90
Study 18037776 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (50 mg/day)/HCTZ (12.5 mg/day)
Number of subjects: 31
Study 18037776 — intervention group
Group type: COMPARATOR
Intervention: candesartan (8 mg/day)/amlodipine (5 mg/day)
Number of subjects: 31
Study 16116345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin or Simvastatin
Number of subjects: 59
Study 16116345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate or Fenofibrate
Number of subjects: 59
Study 16116345 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 12184480 — intervention group
Group type: EXPERIMENTAL
Intervention: Elated mood condition (induced by music and film)
Number of subjects: 0
Study 12184480 — intervention group
Group type: COMPARATOR
Intervention: Sad mood condition (attempted induction through music and film)
Number of subjects: 0
Study 10471591 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of levofloxacin once daily for 14 days
Number of subjects: 30
Study 10471591 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of levofloxacin three times weekly for 14 days
Number of subjects: 30
Study 10471591 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 14 days
Number of subjects: 30
Study 10471591 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times weekly for 14 days
Number of subjects: 30
Study 8731513 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression sclerotherapy using hypertonic saline
Number of subjects: 41
Study 8731513 — intervention group
Group type: COMPARATOR
Intervention: High ligation of sapheno-femoral junction and local excision of varices (Control)
Number of subjects: 41
Study 2116819 — intervention group
Group type: EXPERIMENTAL
Intervention: enprostil 35 micrograms bd
Number of subjects: 77
Study 2116819 — intervention group
Group type: COMPARATOR
Intervention: pirenzepine 50 mg bd
Number of subjects: 77
Study 7094195 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bicycle ergometer
Number of subjects: 18
Study 7094195 — intervention group
Group type: COMPARATOR
Intervention: Standard bicycle ergometer
Number of subjects: 18
Study 31910872 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates solo or belly dance classes three times per week for 16 weeks
Number of subjects: 0
Study 31910872 — intervention group
Group type: COMPARATOR
Intervention: Control group (receipt of a booklet on physical activity and maintenance of habitual physical activity routine)
Number of subjects: 0
Study 30601291 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOFL contact lens
Number of subjects: 16
Study 30601291 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOFH contact lens
Number of subjects: 16
Study 30601291 — intervention group
Group type: COMPARATOR
Intervention: Single Vision (SV) contact lens
Number of subjects: 16
Study 27765556 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 451
Study 27765556 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 451
Study 26773104 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming exercise training
Number of subjects: 48
Study 26773104 — intervention group
Group type: COMPARATOR
Intervention: Cycling exercise training
Number of subjects: 48
Study 25061219 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLR
Number of subjects: 32
Study 25061219 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 24187901 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement plus low-dose aspirin (500 mg carbonate calcium plus 80 mg aspirin)
Number of subjects: 42
Study 24187901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 19815692 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine
Number of subjects: 0
Study 19815692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer treatment
Number of subjects: 0
Study 17934663 — intervention group
Group type: EXPERIMENTAL
Intervention: HBP+DM2 group
Number of subjects: 89
Study 17934663 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients with DM2
Number of subjects: 89
Study 17934663 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 89
Study 16326339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% levobupivacaine infusion
Number of subjects: 32
Study 16326339 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 32
Study 16326339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 12191747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg o.d.
Number of subjects: 12
Study 12191747 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg o.d.
Number of subjects: 12
Study 9790371 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 16 mg 3 times daily, tapered over 2 weeks
Number of subjects: 40
Study 9790371 — intervention group
Group type: COMPARATOR
Intervention: Promethazine, 25 mg 3 times daily, continued for 2 weeks
Number of subjects: 40
Study 9790371 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 40
Study 9790371 — intervention group
Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 40
Study 7608705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ictal SPECT
Number of subjects: 177
Study 7608705 — intervention group
Group type: EXPERIMENTAL
Intervention: Postictal SPECT
Number of subjects: 177